Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.25
AEGR's Cash to Debt is ranked lower than
92% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. AEGR: 0.25 )
Ranked among companies with meaningful Cash to Debt only.
AEGR' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 7.53 Max: No Debt
Current: 0.25
Equity to Asset 0.27
AEGR's Equity to Asset is ranked lower than
88% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AEGR: 0.27 )
Ranked among companies with meaningful Equity to Asset only.
AEGR' s Equity to Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.39 Max: 0.79
Current: 0.27
0.27
0.79
F-Score: 5
Z-Score: -0.78
M-Score: 444.08
WACC vs ROIC
4.70%
-18.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -18.84
AEGR's Operating margin (%) is ranked higher than
61% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. AEGR: -18.84 )
Ranked among companies with meaningful Operating margin (%) only.
AEGR' s Operating margin (%) Range Over the Past 10 Years
Min: -128.43  Med: -18.84 Max: -16.86
Current: -18.84
-128.43
-16.86
Net-margin (%) -30.57
AEGR's Net-margin (%) is ranked higher than
59% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. AEGR: -30.57 )
Ranked among companies with meaningful Net-margin (%) only.
AEGR' s Net-margin (%) Range Over the Past 10 Years
Min: -130.51  Med: -30.57 Max: -24.87
Current: -30.57
-130.51
-24.87
ROE (%) -50.67
AEGR's ROE (%) is ranked lower than
62% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. AEGR: -50.67 )
Ranked among companies with meaningful ROE (%) only.
AEGR' s ROE (%) Range Over the Past 10 Years
Min: -105.89  Med: -73.06 Max: -28.82
Current: -50.67
-105.89
-28.82
ROA (%) -16.76
AEGR's ROA (%) is ranked higher than
60% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. AEGR: -16.76 )
Ranked among companies with meaningful ROA (%) only.
AEGR' s ROA (%) Range Over the Past 10 Years
Min: -189.06  Med: -58.90 Max: -14.2
Current: -16.76
-189.06
-14.2
ROC (Joel Greenblatt) (%) -104.89
AEGR's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. AEGR: -104.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AEGR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -88019.35  Med: -14152.77 Max: -152.77
Current: -104.89
-88019.35
-152.77
EBITDA Growth (3Y)(%) -32.20
AEGR's EBITDA Growth (3Y)(%) is ranked lower than
84% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. AEGR: -32.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AEGR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -32.20 Max: 20.3
Current: -32.2
0
20.3
EPS Growth (3Y)(%) -1.10
AEGR's EPS Growth (3Y)(%) is ranked higher than
53% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. AEGR: -1.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AEGR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -34.40 Max: 1.8
Current: -1.1
0
1.8
» AEGR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AEGR Guru Trades in Q1 2015

Steven Cohen Sold Out
» More
Q2 2015

AEGR Guru Trades in Q2 2015

Jim Simons 159,575 sh (New)
» More
Q3 2015

AEGR Guru Trades in Q3 2015

Jim Simons 232,800 sh (+45.89%)
» More
Q4 2015

AEGR Guru Trades in Q4 2015

John Paulson 26,400 sh (New)
Paul Tudor Jones 22,900 sh (New)
Jim Simons 125,900 sh (-45.92%)
» More
» Details

Insider Trades

Latest Guru Trades with AEGR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Aegerion Pharmaceuticals Inc

Stocks Fall to 5-Year Lows Rosetta Stone, Aegerion Pharmaceuticals, JMP Group, Five Star Quality Care tumble
According to GuruFocus, these guru stocks have reached their five-year lows: Rosetta Stone Inc. (NYSE:RST), Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), JMP Group LLC (NYSE:JMP) and Five Star Quality Care Inc. (NYSE:FVE). Read more...

Ratios

vs
industry
vs
history
P/B 0.72
AEGR's P/B is ranked higher than
95% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. AEGR: 0.72 )
Ranked among companies with meaningful P/B only.
AEGR' s P/B Range Over the Past 10 Years
Min: 0.72  Med: 5.68 Max: 24.7
Current: 0.72
0.72
24.7
P/S 0.35
AEGR's P/S is ranked higher than
98% of the 674 Companies
in the Global Biotechnology industry.

( Industry Median: 11.42 vs. AEGR: 0.35 )
Ranked among companies with meaningful P/S only.
AEGR' s P/S Range Over the Past 10 Years
Min: 0.34  Med: 7.18 Max: 1693.72
Current: 0.35
0.34
1693.72
PFCF 5.79
AEGR's PFCF is ranked higher than
92% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 30.93 vs. AEGR: 5.79 )
Ranked among companies with meaningful PFCF only.
AEGR' s PFCF Range Over the Past 10 Years
Min: 5.79  Med: 15.21 Max: 23.47
Current: 5.79
5.79
23.47
POCF 5.12
AEGR's POCF is ranked higher than
92% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 25.07 vs. AEGR: 5.12 )
Ranked among companies with meaningful POCF only.
AEGR' s POCF Range Over the Past 10 Years
Min: 5.12  Med: 16.15 Max: 377.57
Current: 5.12
5.12
377.57
Current Ratio 2.02
AEGR's Current Ratio is ranked lower than
77% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. AEGR: 2.02 )
Ranked among companies with meaningful Current Ratio only.
AEGR' s Current Ratio Range Over the Past 10 Years
Min: 0.09  Med: 6.77 Max: 28.72
Current: 2.02
0.09
28.72
Quick Ratio 1.35
AEGR's Quick Ratio is ranked lower than
81% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. AEGR: 1.35 )
Ranked among companies with meaningful Quick Ratio only.
AEGR' s Quick Ratio Range Over the Past 10 Years
Min: 0.09  Med: 6.74 Max: 28.72
Current: 1.35
0.09
28.72
Days Inventory 319.40
AEGR's Days Inventory is ranked lower than
86% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 120.79 vs. AEGR: 319.40 )
Ranked among companies with meaningful Days Inventory only.
AEGR' s Days Inventory Range Over the Past 10 Years
Min: 59.63  Med: 141.61 Max: 237.89
Current: 319.4
59.63
237.89
Days Sales Outstanding 20.63
AEGR's Days Sales Outstanding is ranked higher than
84% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. AEGR: 20.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
AEGR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.63  Med: 39.47 Max: 56.93
Current: 20.63
20.63
56.93
Days Payable 75.22
AEGR's Days Payable is ranked higher than
55% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 63.23 vs. AEGR: 75.22 )
Ranked among companies with meaningful Days Payable only.
AEGR' s Days Payable Range Over the Past 10 Years
Min: 75.22  Med: 246.71 Max: 301
Current: 75.22
75.22
301

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.05
AEGR's Price/Median PS Value is ranked higher than
99% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. AEGR: 0.05 )
Ranked among companies with meaningful Price/Median PS Value only.
AEGR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.17  Med: 0.54 Max: 5.87
Current: 0.05
0.17
5.87
Price/Graham Number 0.17
AEGR's Price/Graham Number is ranked higher than
96% of the 292 Companies
in the Global Biotechnology industry.

( Industry Median: 2.51 vs. AEGR: 0.17 )
Ranked among companies with meaningful Price/Graham Number only.
AEGR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.62  Med: 0.62 Max: 0.62
Current: 0.17
Earnings Yield (Greenblatt) (%) -16.40
AEGR's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. AEGR: -16.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AEGR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -16.4  Med: 0.00 Max: 0
Current: -16.4
-16.4
0

More Statistics

Revenue(Mil) $240
EPS $ -2.54
Beta2.13
Short Percentage of Float32.35%
52-Week Range $2.80 - 25.06
Shares Outstanding(Mil)29.47

Business Description

Industry: Biotechnology » Biotechnology
Compare:TPE:1734, ASX:VLA, NAS:AFMD, NAS:DPRX, XPAR:CEREN, TSX:HBP » details
Traded in other countries:KYE.Germany,
Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc., and Alnylam Pharmaceuticals, Inc. The Company's operations are subject to federal, state and local level, the EU and other countries extensively regulations.
» More Articles for AEGR

Headlines

Articles On GuruFocus.com
Stocks Reach 5-Year Lows Apr 11 2016 
Stocks Reach 5-year Lows Apr 04 2016 
Stocks Fall to 5-Year Lows Mar 28 2016 
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 
Weekly CEO Buys Highlight: GEO, TRUE, BANC, AEGR, CLMS Jun 02 2014 
Three CEOs Reporting Large Insider Buys May 22 2014 
Four CEOs Reporting Large Insider Buys May 09 2014 
100 Stocks at All-Time Highs | 60 Dividend Stocks Below the Results Feb 19 2013 
My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List Dec 27 2012 

More From Other Websites
Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA Apr 29 2016
Aegerion (AEGR): Can the Stock Surprise in Q1 Earnings? Apr 27 2016
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Apr 11 2016
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Apr 11 2016
Stocks Reach 5-Year Lows Apr 11 2016
The Zacks Analyst Blog Highlights: QLT, Twitter, Aegerion Pharmaceuticals, Linn and Lenovo Group Apr 07 2016
5 Stocks Near 52-Week Lows But Still Worth Buying Apr 06 2016
Stocks Reach 5-year Lows Apr 04 2016
5 Stocks Under $10 Set to Soar Mar 31 2016
Aegerion Pharmaceuticals Observes World Lipodystrophy Day Mar 31 2016
Aegerion Pharmaceuticals Observes World Lipodystrophy Day Mar 31 2016
Stocks Fall to 5-Year Lows Mar 28 2016
Aegerion Pharmaceuticals (AEGR) Is in Oversold Territory: What's Next? Mar 23 2016
Sarissa Capital Management and Aegerion Pharmaceuticals, Inc. (AEGR) Amend Nomination Agreement Mar 22 2016
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 22 2016
AEGERION PHARMACEUTICALS, INC. Financials Mar 19 2016
AEGERION PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 15 2016
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Mar 10 2016
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 10 2016
$100 Billion French Pharma Giant Sanofi says they're on the "Hunt" for Rare Disease Acquisitions:... Mar 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK